Semaglutide (Ozempic / Wegovy)

Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone secreted by intestinal L-cells in response to food intake. Structurally, it shares approximately 94% sequence homology with endogenous GLP-1 but incorporates a C18 fatty diacid chain attached via a linker to lysine at position 26, which enables albumin binding and dramatically extends its half-life to approximately 165–168 hours — enabling once-weekly subcutaneous dosing. It belongs to the GLP-1 receptor agonist class alongside liraglutide (Victoza/Saxenda), dulaglutide (Trulicity), and the dual GIP/GLP-1 agonist tirzepatide. Semaglutide also exists in an oral formulation (Rybelsus), which uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to facilitate uptake across the gastric mucosa.

Semaglutide's mechanism of action is multifactorial. At the pancreatic level, it stimulates glucose-dependent insulin secretion and suppresses glucagon release, improving glycemic control without causing hypoglycemia in isolation. At the central nervous system level, research suggests GLP-1 receptors in the hypothalamus and brainstem — particularly the arcuate nucleus and area postrema — mediate reductions in appetite and food-reward signaling. Animal models and human neuroimaging studies indicate semaglutide attenuates the reinforcing properties of palatable foods, which may partially explain the appetite suppression reported beyond simple gastric emptying delay. Gastric motility is also slowed, contributing to earlier satiety. Cardiovascular benefits observed in the SELECT trial (2023) — a reduction in major adverse cardiovascular events (MACE) in adults with obesity and established cardiovascular disease — suggest additional vascular and inflammatory mechanisms that are still under active investigation.

The evidence base for semaglutide is among the strongest of any compound covered on this platform. The STEP 1 trial (n=1,961, 2021, New England Journal of Medicine) demonstrated a mean body weight reduction of approximately 14.9% over 68 weeks in adults with obesity receiving 2.4 mg subcutaneous semaglutide weekly, versus 2.4% in the placebo group. The SUSTAIN trial series established glycemic efficacy across multiple comparators in type 2 diabetes populations. The SELECT trial (n=17,604, 2023) reported a 20% relative risk reduction in MACE in adults with overweight/obesity and cardiovascular disease, without diabetes as an inclusion criterion — a landmark finding that significantly expanded the clinical rationale for semaglutide beyond metabolic endpoints. Pediatric data are emerging: the FDA approved Wegovy for adolescents aged 12 and older in 2023 based on the STEP TEENS trial. Evidence for cognitive and addiction-related applications (alcohol use disorder, smoking cessation) is preliminary and largely observational or early-phase at time of writing; no regulatory approvals exist for these indications.

Dosing reported in research contexts follows a structured escalation protocol designed to minimize gastrointestinal side effects. For the weight management indication (Wegovy), published trials used a 16-week escalation: 0.25 mg/week for 4 weeks, then 0.5 mg/week, then 1.0 mg/week, then 1.7 mg/week, reaching the maintenance dose of 2.4 mg/week. For the diabetes indication (Ozempic), the escalation ceiling is 1.0 mg/week (or 2.0 mg in some markets). Oral semaglutide (Rybelsus) is studied at 3 mg, 7 mg, and 14 mg daily doses. These ranges are reported here for educational and research context only — they are not dosing recommendations. Semaglutide is a prescription drug; any use should be supervised by a licensed healthcare provider who can assess contraindications, manage titration, and monitor for adverse events. Compounded semaglutide from non-pharmacy sources is specifically addressed under sourcing considerations below.

Semaglutide is FDA-approved (US), EMA-approved (EU), MHRA-approved (UK), and TGA-approved (Australia) for specific indications accessed via prescription. It is not a research chemical and should not be sourced through peptide research chemical vendors. During a period of FDA-declared shortage (2022–2024), compounded semaglutide was legally permitted from 503A and 503B pharmacies in the US; the FDA began removing semaglutide from the shortage list in 2025, which significantly restricts the legality of compounded versions going forward. Telehealth platforms such as Ro, Hims/Hers, and Mochi Health have offered legitimate prescription pathways; the regulatory landscape for compounded versions is actively shifting and patients should consult current FDA guidance. Sourcing semaglutide from unregulated peptide vendors — where it may be mislabeled, underdosed, or contaminated — is strongly discouraged and carries meaningful health and legal risk. This content is for educational purposes only and does not constitute medical advice.